|
1
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: Epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:3161–594.
2008. View Article : Google Scholar
|
|
2
|
Chen Z, Fillmore CM, Hammerman PS, Kim CF
and Wong KK: Non-small-cell lung cancers: A heterogeneous set of
diseases. Nat Rev Cancer. 14:535–546. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wood SL, Pernemalm M, Crosbie PA and
Whetton AD: The role of the tumor-microenvironment in lung
cancer-metastasis and its relationship to potential therapeutic
targets. Cancer Treat Rev. 40:558–566. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
de Perrot M, Fadel E, Mussot S, de Palma
A, Chapelier A and Dartevelle P: Resection of locally advanced (T4)
non-small cell lung cancer with cardiopulmonary bypass. Ann Thorac
Surg. 79:1691–1697. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wu H, Zhou J, Mei S, Wu D, Mu Z, Chen B,
Xie Y, Ye Y and Liu J: Circulating exosomal microRNA-96 promotes
cell proliferation, migration and drug resistance by targeting
LMO7. J Cell Mol Med. 21:1228–1236. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Joshi P, Jeon YJ, Laganà A, Middleton J,
Secchiero P, Garofalo M and Croce CM: MicroRNA-148a reduces
tumorigenesis and increases TRAIL-induced apoptosis in NSCLC. Proc
Natl Acad Sci USA. 112:8650–8655. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fedoriw A, Rajapurkar SR, O'Brien S,
Gerhart SV, Mitchell LH, Adams ND, Rioux N, Lingaraj T, Ribich SA,
Pappalardi MB, et al: Anti-tumor activity of the type I PRMT
inhibitor, GSK3368715, synergizes with PRMT5 inhibition through
MTAP loss. Cancer Cell. 36:100–114.e25. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bedford MT and Clarke SG: Protein arginine
methylation in mammals: Who, what, and why. Mol Cell. 33:1–13.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pahlich S, Zakaryan RP and Gehring H:
Protein arginine methylation: Cellular functions and methods of
analysis. Biochim Biophys Acta. 1764:1890–1903. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Blanc RS and Richard S: Arginine
methylation: The coming of age. Mol Cell. 65:8–24. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bowitch A, Michaels KL, Yu MC and Ferkey
DM: The protein arginine methyltransferase PRMT-5 regulates SER-2
tyramine receptor-mediated behaviors in caenorhabditis elegans. G3
(Bethesda). 8:2389–2398. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Altan B, Yokobori T, Ide M, Mochiki E,
Toyomasu Y, Kogure N, Kimura A, Hara K, Bai T, Bao P, et al:
Nuclear PRMT1 expression is associated with poor prognosis and
chemosensitivity in gastric cancer patients. Gastric Cancer.
19:789–797. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yoshimatsu M, Toyokawa G, Hayami S, Unoki
M, Tsunoda T, Field HI, Kelly JD, Neal DE, Maehara Y, Ponder BA, et
al: Dysregulation of PRMT1 and PRMT6, Type I arginine
methyltransferases, is involved in various types of human cancers.
Int J Cancer. 128:562–573. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Almeida-Rios D, Graça I, Vieira FQ,
Ramalho-Carvalho J, Pereira-Silva E, Martins AT, Oliveira J,
Gonçalves CS, Costa BM, Henrique R and Jerónimo C: Histone
methyltransferase PRMT6 plays an oncogenic role of in prostate
cancer. Oncotarget. 7:53018–53028. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Greenblatt SM, Man N, Hamard PJ, Asai T,
Karl D, Martinez C, Bilbao D, Stathias V, Jermakowicz AM, Duffort
S, et al: CARM1 is essential for myeloid leukemogenesis but
dispensable for normal hematopoiesis. Cancer Cell. 35:1562019.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cheung N, Chan LC, Thompson A, Cleary ML
and So CW: Protein arginine-methyltransferase-dependent
oncogenesis. Nat Cell Biol. 9:1208–1215. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Elakoum R, Gauchotte G, Oussalah A,
Wissler MP, Clément-Duchêne C, Vignaud JM, Guéant JL and Namour F:
CARM1 and PRMT1 are dysregulated in lung cancer without
hierarchical features. Biochimie. 97:210–218. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li M, An W, Xu L, Lin Y, Su L and Liu X:
The arginine methyltransferase PRMT5 and PRMT1 distinctly regulate
the degradation of anti-apoptotic protein CFLARL in
human lung cancer cells. J Exp Clin Cancer Res. 38:642019.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zakrzewicz D, Didiasova M, Krüger M,
Giaimo BD, Borggrefe T, Mieth M, Hocke AC, Zakrzewicz A, Schaefer
L, Preissner KT and Wygrecka M: Protein arginine methyltransferase
5 mediates enolase-1 cell surface trafficking in human lung
adenocarcinoma cells. Biochim Biophys Acta Mol Basis Dis.
1864:1816–1827. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Frankel A, Yadav N, Lee J, Branscombe TL,
Clarke S and Bedford MT: The novel human protein arginine
N-methyltransferase PRMT6 is a nuclear enzyme displaying unique
substrate specificity. J Biol Chem. 277:3537–3543. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Limm K, Ott C, Wallner S, Mueller DW,
Oefner P, Hellerbrand C and Bosserhoff AK: Deregulation of protein
methylation in melanoma. Eur J Cancer. 49:1305–1313. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chan LH, Zhou L, Ng KY, Wong TL, Lee TK,
Sharma R, Loong JH, Ching YP, Yuan YF, Xie D, et al: PRMT6
regulates RAS/RAF binding and MEK/ERK-mediated cancer stemness
activities in hepatocellular carcinoma through CRAF methylation.
Cell Rep. 25:690–701 e698. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Veland N, Hardikar S, Zhong Y, Gayatri S,
Dan J, Strahl BD, Rothbart SB, Bedford MT and Chen T: The arginine
methyltransferase PRMT6 regulates DNA methylation and contributes
to global DNA hypomethylation in cancer. Cell Rep. 21:3390–3397.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sellers AH: The clinical classification of
malignant tumours: The TNM system. Can Med Assoc J. 105:836passim.
1971.PubMed/NCBI
|
|
25
|
Wohlschläger J, Wittekind C and Theegarten
D: New TNM classification of malignant lung tumours. Pathologe.
31:355–360. 2010.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Feldman AT and Wolfe D: Tissue processing
and hematoxylin and eosin staining. Methods Mol Biol. 1180:31–43.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shechter D, Dormann HL, Allis CD and Hake
SB: Extraction, purification and analysis of histones. Nat Protoc.
2:1445–1457. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhao Q, Rank G, Tan YT, Li H, Moritz RL,
Simpson RJ, Cerruti L, Curtis DJ, Patel DJ, Allis CD, et al:
PRMT5-mediated methylation of histone H4R3 recruits DNMT3A,
coupling histone and DNA methylation in gene silencing. Nat Struct
Mol Biol. 16:304–311. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Clark JD, Gebhart GF, Gonder JC, Keeling
ME and Kohn DF: Special report: The 1996 Guide for the Care and Use
of Laboratory Animals. ILAR J. 38:41–48. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gong S, Qu X, Yang S, Zhou S, Li P and
Zhang Q: RFC3 induces epithelialmesenchymal transition in lung
adenocarcinoma cells through the Wnt/β-catenin pathway and
possesses prognostic value in lung adenocarcinoma. Int J Mol Med.
44:2276–2288. 2019.PubMed/NCBI
|
|
32
|
Sherr CJ and Roberts JM: CDK inhibitors:
Positive and negative regulators of G1-phase progression. Genes
Dev. 13:1501–1512. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Guan KL, Jenkins CW, Li Y, Nichols MA, Wu
X, O'Keefe CL, Matera AG and Xiong Y: Growth suppression by p18, a
p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates
with wild-type pRb function. Genes Dev. 8:2939–2952. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Stein C, Riedl S, Ruthnick D, Nötzold RR
and Bauer UM: The arginine methyltransferase PRMT6 regulates cell
proliferation and senescence through transcriptional repression of
tumor suppressor genes. Nucleic Acids Res. 40:9522–9533. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Auclair Y and Richard S: The role of
arginine methylation in the DNA damage response. DNA Repair (Amst).
12:459–465. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Biggar KK and Li SS: Non-histone protein
methylation as a regulator of cellular signalling and function. Nat
Rev Mol Cell Biol. 16:5–17. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Malumbres M and Carnero A: Cell cycle
deregulation: A common motif in cancer. Prog Cell Cycle Res.
5:5–18. 2003.PubMed/NCBI
|
|
38
|
AbuHammad S, Cullinane C, Martin C,
Bacolas Z, Ward T, Chen H, Slater A, Ardley K, Kirby L, Chan KT, et
al: Regulation of PRMT5-MDM4 axis is critical in the response to
CDK4/6 inhibitors in melanoma. Proc Natl Acad Sci USA.
116:17990–18000. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Raposo AE and Piller SC: Protein arginine
methylation: An emerging regulator of the cell cycle. Cell Div.
13:32018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kleinschmidt MA, de Graaf P, van Teeffelen
HA and Timmers HT: Cell cycle regulation by the PRMT6 arginine
methyltransferase through repression of cyclin-dependent kinase
inhibitors. PLoS One. 7:e414462012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Phalke S, Mzoughi S, Bezzi M, Jennifer N,
Mok WC, Low DH, Thike AA, Kuznetsov VA, Tan PH, Voorhoeve PM and
Guccione E: p53-independent regulation of p21Waf1/Cip1 expression
and senescence by PRMT6. Nucleic Acids Res. 40:9534–9542. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Guccione E, Bassi C, Casadio F, Martinato
F, Cesaroni M, Schuchlautz H, Lüscher B and Amati B: Methylation of
histone H3R2 by PRMT6 and H3K4 by an MLL complex are mutually
exclusive. Nature. 449:933–937. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hyllus D, Stein C, Schnabel K, Schiltz E,
Imhof A, Dou Y, Hsieh J and Bauer UM: PRMT6-mediated methylation of
R2 in histone H3 antagonizes H3 K4 trimethylation. Genes Dev.
21:3369–3380. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kirmizis A, Santos-Rosa H, Penkett CJ,
Singer MA, Vermeulen M, Mann M, Bähler J, Green RD and Kouzarides
T: Arginine methylation at histone H3R2 controls deposition of H3K4
trimethylation. Nature. 449:928–932. 2007. View Article : Google Scholar : PubMed/NCBI
|
